No placental MSC or chondrocyte product for hip OA has FDA approval as a disease-modifying therapy. Investigational products have been used under clinical-trial exemptions. The EU has not formally approved any such product through EMA marketing authorisation, though some operate under ATMP or medical-device pathways with national regulatory flexibility.
Hip osteoarthritis (OA) develops when protective cartilage lining the femoral head and acetabulum undergoes progressive degradation—triggered by mechanical wear, inflammation, prior injury, or metabolic dysfunction—exposing the underlying bone. Cartilage lesions enlarge, bone spurs form, and synovial fluid (joint lubricant) becomes inflamed. Pain, stiffness, and loss of range of motion ensue, eventually limiting walking and activities of daily living. Cell therapy in hip OA leverages placental MSCs, engineered chondrocytes, and exosomes to deliver anti-inflammatory and cartilage-regenerative signals directly into the joint. Intra-articular injection (into the joint space) positions cells to interact with damaged cartilage surfaces, synovial tissue, and local immune cells, potentially slowing degeneration or promoting cartilage matrix repair.
我是候选人吗？ → · Hip Osteoarthritis: full overview → · 髋关节骨关节炎成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估